Navigation Links
Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
Date:7/23/2012

CAMBRIDGE, Mass., July 23, 2012 /PRNewswire/ -- Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

Having completed enrollment of a 150-patient randomized Phase 2 study in advanced non-small cell lung cancer, Cerulean is beginning to capitalize on the breadth of the CRLX101 opportunity by expanding its development into additional tumor types with several studies conducted by leading investigators.  This newly opened trial is designed to evaluate the activity of CRLX101, a nanopharmaceutical that inhibits both topoisomerase 1 and hypoxia-inducible factor-1 alpha, in ovarian cancer patients whose disease has progressed following standard first-line platinum-based therapy.  Current approved second-line therapy for ovarian cancer includes use of the topoisomerase 1 inhibitor, topotecan, which has limitations.  The study is being conducted at the Massachusetts General Hospital and led by principal investigator Carolyn Krasner, M.D., in cooperation with the Dana Farber Cancer Institute, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center.  

"Not only do women with advanced stage ovarian cancer have limited treatment options, but they also suffer from many disease-related symptoms and treatment-related side effects," said Dr. Krasner.  "This study will enable us to evaluate the potential use of CRLX101 as a treatment option for those patients." 

"This trial is intended to build on our current clinical data and determine if CRLX101 can offer ovarian cancer patients a new treatment option," said Edward Garmey, M.D., chief medical officer of Cerulean.  "We are excited to partner with Dr. Krasner and to expand the development strategy of CRLX101 in an indication w
'/>"/>

SOURCE Cerulean Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
2. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
3. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
4. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
5. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. China Health Resource Announces Go Global Initiative For New Product Introductions
7. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract
9. Ampio Pharmaceuticals Announces Closing of Public Offering
10. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
11. Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 A decade-long JDRF-funded study ... Zentrum München, Germany , is providing ... the risk of developing type 1 diabetes (T1D), highlighting ... the disease. The study, "Seroconversion to Multiple Islet Autoantibodies ... published today in The Journal of the American ...
(Date:6/19/2013)... 2013   Voices Against Brain Cancer (VABC), ... brain cancer, today announced that it has awarded Tocagen ... clinical investigation of Toca 511 & Toca FC in ... cancer (Grade 3 or Grade 4).  Tocagen is a ... cancer, with an initial focus on brain cancer. ...
(Date:6/19/2013)... 2013 Amerivet Solutions, LLC ( AMERIVET ... of government from Federal to Municipal, is pleased ... to include complex metal design and fabrication manufacturing. ... complex aluminum parts for the Defense Logistics Agency ... to service government contracts," states Richard Bergen ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
(Date:6/20/2013)... 2013 David Icke, the highly visible alternative ... Radio station. , Fresh from the Bilderburg fringe festival ... getting ready to launch ‘The Peoples Voice’ TV and Radio ... a fantastic opportunity for journalists to cover the stories and ... of the globe. , Because this station is for ...
(Date:6/20/2013)... Norwalk, CT (PRWEB) June 20, 2013 ... looking to energize their sales or test new markets, ... the U.S. now have a new sales outsourcing ... and sustained sales revenue. , Strategy Sales ... sales professionals. Founded by business owners for business owners, ...
(Date:6/20/2013)... June 20, 2013 The University of ... its new, online Master of Science in Nursing ... Master’s Education in Nursing from the American Association of ... the foundation of most major nursing master’s degree programs ... program from the University of Saint Mary not only ...
(Date:6/19/2013)... June 19, 2013 Paleo Burn has finally ... people finally sculpt the body they desire with no fad ... loss programs and health food products, Ken Smith was bold ... give consumers an easy, automatic, and permanent solution for weight ... details . , After a quick review of Paleo Burn, ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 The Zac ... in the country and folk music genre. This band hails ... is the lead vocals and guitarist), Jimmy De Martini (working ... bass guitarist and in vocals), Coy Bowles (guitarist and keyboardist), ... Reyes (percussionist). The band was formed in 2002, but ...
Breaking Medicine News(10 mins):Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 2Health News:Strategy Sales Partners Launches to Provide Sales Outsourcing Assistance to Businesses 3Health News:University of Saint Mary Launches New Online Master of Science in Nursing Built on the Latest AACN Essentials 2Health News:University of Saint Mary Launches New Online Master of Science in Nursing Built on the Latest AACN Essentials 3Health News:Paleo Burn Review Released by TotalWellnessCleanse.net 2Health News:Zac Brown Band Tickets for Raleigh, Columbia, Darien Center, Gilford, Minneapolis, Holmdel, Pittsburgh, Camden, Atlanta, Boston, Bethel, Toronto & Hartford Now Available 2
... of great public health importance in tropical countries. James ... episodes are associated with transient increases of HIV-1 viral ... episodes might accelerate HIV-1 disease progression and facilitate transmission. ... effects of HIV-1 infection on malaria. In pregnant women ...
... Toyama University, Japan have found that supplementation of fish ... //Researchers have found that Docosahexaenoic acid (DHA), which is ... component of cell membranes of the retina and brain. ... have lower concentrations of DHA in blood. , ...
... colleagues from United Kingdom have found a new antibiotic ... of Tetracycline known as Glycycline. // ,Due to ... of antibiotic resistance shown by many organisms. Staphylococcus aureus ... cause of concern as it causes most of the ...
... continues to grow and currently affects more that ... emphasize a need for alternative diabetes therapies with ... ,The delivery of insulin by the lung may ... diabetes. However, alternative insulin delivery systems must meet ...
... Bird Flu epidemic that is causing chaos in Turkey and ... the viral strain H5N1//. , ,The migratory bird ... affected by the deadly virus strain H5N1 that can kill ... due to the direct contact with affected and sick birds. ...
... hematopoietic-cell transplantation with the use of conditioning ... to decrease early toxic effects extends the ... than 50 years and those with coexisting ... (GVHD) remains a major problem after non-myeloablative ...
Cached Medicine News:Health News:Malaria infection can accelerate HIV infection and disease progression 2Health News:Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit 2Health News:HIIP- A Novel Inhaled Insulin Delivery System As An Alternative To Injectable Insulin Therapy 2Health News:Protective regimen for acute Graft-versus-host disease 2
The Avant® 9700 combines flexible alarm options, unparalleled non-volatile memory, and Nonins time-honored technology to give you an easy-to-use and efficient monitor....
... Resolve Immersion Oil is a clear, ... throughout most of the UV-VIS spectrum. ... and high viscosity, is non-drying and ... of 1.5150. Resolve contains no PCBs, ...
Immersion Oil, 150 cs...
Immersion oil for microscopy...
Medicine Products: